Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia

Inclusion Criteria: * Participants aged ≥ 19 years * Participants who have voluntarily given written consent to participate in this clinical trial * Participants with LDL-C ≤ 250mg/dL and TG \< 500mg/dL at Visit 1 * Participants with LDL-C ≤ 250mg/dL, TG \< 500 mg/dL and satisfied criteria according to cardiovascular risk category at Visit 2 (after at least 4 weeks of TLC) Exclusion Criteria: * Patients with active liver disease and severe liver impairment * Patients with severe renal failure (eGFR \< 30 mL/min/1.73 m2 at Visit 1) * Patients with type I diabetes or uncontrolled type 2 diabetes * Patients with acute hypertension or uncontrolled hypertension (sitSBP ≥ 180 mmHg or sitDBP ≥ 110 mmHg at Visit 1) * Patients with symptomatic orthostatic hypotension * Patients with NYHA class III\~IV heart failure, CCSA class III\~IV angina, ventricular arrhythmia, severe hemorrhagic or ischemic cerebrovascular diseases, transient ischemic attacks (TIAs), acute coronary syndrome or a history of angioplasty, percutaneous coronary intervention, or coronary artery bypass surgery within six months before Visit 1. * Patients who were diagnosed with a malignant tumor within five years before Visit.